CFAP221

Across TCGA pan-cancer cohorts, CFAP221 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated CFAP221 data layer compared with 4 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher CFAP221 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated CFAP221 expression acts as an unfavorable survival marker, although some lineages such as MESO and KIRP show a favorable association.

MESO, KIRC, and LUSC are the cancer types where CFAP221 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	III,IV	0.513	0.257	.002	56	view →
KIRC	OS	Median	All	0.840	0.904	<.001	56	view →
LUSC	DFS	Quartile	All	0.287	0.478	.002	22	view →
KIRP	DFS	Median	All	1.000	0.783	.001	22	view →
LUAD	OS	Median	All	0.857	0.767	.002	19	view →
STAD	DFS	Quartile	All	0.379	0.484	.023	18	view →
READ	OS	Tertile	All	0.842	0.969	.016	15	view →
DLBC	OS	Median	II,III,IV	0.747	1.000	.014	12	view →
SARC	DFS	Median	All	0.410	0.284	.023	10	view →
LGG	OS	Median	All	0.765	0.888	.008	9	view →
CHOL	DFS	Median	All	0.727	0.227	.012	9	view →
PAAD	DFS	Median	II,III,IV	0.215	0.375	.023	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

CFAP221–MESO (DFS)

Open the MESO breakdown →